Propanc Biopharma Reports Key Corporate Events
Ticker: PPCB · Form: 8-K · Filed: Aug 19, 2025 · CIK: 1517681
| Field | Detail |
|---|---|
| Company | Propanc Biopharma, Inc. (PPCB) |
| Form Type | 8-K |
| Filed Date | Aug 19, 2025 |
| Risk Level | medium |
| Pages | 4 |
| Reading Time | 5 min |
| Key Dollar Amounts | $0.001, $4.00, $4,000,000, $3,340,000 |
| Sentiment | neutral |
Sentiment: neutral
Topics: material-agreement, corporate-governance, filing-update
TL;DR
Propanc Biopharma filed an 8-K detailing material agreements and officer/director changes.
AI Summary
Propanc Biopharma, Inc. filed an 8-K on August 19, 2025, reporting on several key events that occurred on August 14, 2025. These include entering into a material definitive agreement, changes in directors and officers, and other events. The filing also lists financial statements and exhibits.
Why It Matters
This 8-K filing signals significant corporate activity for Propanc Biopharma, potentially impacting its strategic direction and operational structure.
Risk Assessment
Risk Level: medium — 8-K filings often contain material information that can significantly impact a company's stock price, requiring careful investor attention.
Key Players & Entities
- Propanc Biopharma, Inc. (company) — Registrant
- August 14, 2025 (date) — Earliest event reported
- August 19, 2025 (date) — Date of report
FAQ
What was the nature of the material definitive agreement entered into by Propanc Biopharma?
The filing indicates the entry into a material definitive agreement, but the specific details of this agreement are not provided in the provided text.
Were there any changes to Propanc Biopharma's board of directors or executive officers?
Yes, the filing reports on the departure of directors or certain officers, the election of directors, and the appointment of certain officers.
What is the primary business of Propanc Biopharma, Inc.?
Propanc Biopharma, Inc. is in the Pharmaceutical Preparations industry, SIC code 2834.
In which jurisdiction is Propanc Biopharma, Inc. incorporated?
Propanc Biopharma, Inc. is incorporated in Delaware.
What is the fiscal year end for Propanc Biopharma, Inc.?
The fiscal year end for Propanc Biopharma, Inc. is June 30.
Filing Stats: 1,180 words · 5 min read · ~4 pages · Grade level 10.9 · Accepted 2025-08-19 17:24:52
Key Financial Figures
- $0.001 — ch registered Common Stock, par value $0.001 PPCB The Nasdaq Stock Market LLC
- $4.00 — ommon Stock at a price to the public of $4.00 per share (the " Offering "). In connec
- $4,000,000 — ommon Stock for total gross proceeds of $4,000,000, and (ii) issued the Representative's W
- $3,340,000 — s, the Company received net proceeds of $3,340,000. The foregoing descriptions of the Un
Filing Documents
- form8-k.htm (8-K) — 46KB
- ex1-1.htm (EX-1.1) — 522KB
- ex4-1.htm (EX-4.1) — 106KB
- ex10-1.htm (EX-10.1) — 41KB
- ex10-2.htm (EX-10.2) — 40KB
- ex99-1.htm (EX-99.1) — 14KB
- ex99-2.htm (EX-99.2) — 13KB
- 0001641172-25-024872.txt ( ) — 1100KB
- ppcb-20250814.xsd (EX-101.SCH) — 3KB
- ppcb-20250814_lab.xml (EX-101.LAB) — 33KB
- ppcb-20250814_pre.xml (EX-101.PRE) — 22KB
- form8-k_htm.xml (XML) — 4KB
forward-looking statements
forward-looking statements. Item 9.01 Financial Statements and Exhibits. (d) Exhibits: Exhibit No. Description 1.1 Underwriting Agreement dated August 14, 2025, by and among Propanc Biopharma, Inc., D. Boral Capital, LLC, and Craft Capital Management LLC 4.1 Representative's Warrant dated August 15, 2025 10.1 Independent Director Agreement dated August 14, 2025, by and between Propanc Biopharma, Inc. and Joseph Himy 10.2 Independent Director Agreement dated August 14, 2025, by and between Propanc Biopharma, Inc. and Annie VanBroekhoven 99.1 Press Release dated August 14, 2025 99.2 Press Release dated August 19, 2025 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: August 19, 2025 PROPANC BIOPHARMA, INC. By: /s/ James Nathanielsz Name: James Nathanielsz Title: Chief Executive Officer and Chief Financial Officer